Why the study?
Do serial NT‐proBNP measurements provide incremental prognostic value over baseline measurements for cardiovascular events in adults with congenitally corrected transposition of the great arteries?
Cohort (n=152)
Do serial NT‐proBNP measurements provide incremental prognostic value over baseline measurements for cardiovascular events in adults with congenitally corrected transposition of the great arteries?
Serial NT‐proBNP measurements provide incremental prognostic value over baseline levels for predicting cardiovascular events in adults with congenitally corrected transposition of the great arteries.
Supports serial NT-proBNP testing to guide intervention in ccTGA; extends its prognostic utility for surveillance in adult congenital heart disease.
Background: Cardiovascular biomarkers such as NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) are used for heart failure risk stratification in patients with acquired heart disease, but there are limited data about its role in patients with congenitally corrected transposition of the great arteries. The current study aims to assess the role of serial NT‐proBNP measurements for risk stratification in adults with congenitally corrected transposition of the great arteries. Methods: We studied adults with congenitally corrected transposition of the great arteries with ≥2 NT‐proBNP measurements (2003–2024). Temporal change in NT‐proBNP was calculated as relative change from baseline levels. Results: Of 152 patients (age 47±13 years, 45% men), baseline NT‐proBNP was 539 (interquartile range, 193–1549) pg/mL, and relative change from baseline levels of NT‐proBNP was 34% (interquartile range, −11 to 67). Of 152 patients, 45 (30%) had cardiovascular events (heart failure hospitalization [n=29], ventricular assist device [n=5], heart transplantation [n=11], and death [n=10]), yielding a 10‐year incidence of 26%. Higher baseline NT‐proBNP and relative change from baseline levels were associated with cardiovascular events. Serial NT‐proBNP measurements had incremental prognostic value compared with baseline measurement. The correlates of higher NT‐proBNP levels were atrial fibrillation, hypertension, right ventricular dilation and dysfunction, and atrioventricular valve regurgitation. Renin–angiotensin–aldosterone system antagonist was associated with lower NT‐proBNP levels and lower risk of cardiovascular events. Conclusions: NT‐proBNP testing is inexpensive, widely available, and noninvasive, making it well suited for longitudinal surveillance in adults with congenital heart disease. Most of the correlates for elevated NT‐proBNP levels were modifiable, providing target for therapeutic interventions.
No takes yet. Share an insight, caveat, or question.
Bahnasy et al. (2026) conducted a cohort in Congenitally corrected transposition of the great arteries (n=152). Higher baseline NT-proBNP and relative change from baseline was evaluated on Cardiovascular events (heart failure hospitalization, ventricular assist device, heart transplantation, and death).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: